Syros Pharmaceuticals IncNASDAQ:SYRS
- LAST PRICE5.1400
- TODAY'S CHANGE (%)0.1500 (3.0060%)
- Bid / Lots4.9800/ 1
- Ask / Lots5.9800/ 1
- Open / Previous Close4.9800 / 4.9900
- Day Range
- 52 Week Range
- Volume172,679
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SYRS |
|---|---|---|
| 09:32 ET | 1295 | 4.98 |
| 09:43 ET | 127 | 4.9809 |
| 09:48 ET | 700 | 5.1 |
| 09:50 ET | 200 | 5.13 |
| 09:52 ET | 100 | 5.2 |
| 09:54 ET | 320 | 5.2399 |
| 09:56 ET | 1130 | 5.24 |
| 09:57 ET | 100 | 5.32 |
| 09:59 ET | 700 | 5.27 |
| 10:03 ET | 8747 | 5.2 |
| 10:06 ET | 100 | 5.27 |
| 10:08 ET | 1000 | 5.2 |
| 10:10 ET | 1318 | 5.185 |
| 10:12 ET | 4470 | 5.28 |
| 10:14 ET | 300 | 5.22 |
| 10:19 ET | 500 | 5.26 |
| 10:26 ET | 500 | 5.25 |
| 10:28 ET | 1545 | 5.28 |
| 10:32 ET | 505 | 5.32 |
| 10:33 ET | 300 | 5.3049 |
| 10:35 ET | 2414 | 5.25 |
| 10:46 ET | 100 | 5.21 |
| 10:48 ET | 800 | 5.23 |
| 10:51 ET | 300 | 5.25 |
| 10:53 ET | 500 | 5.265 |
| 11:00 ET | 100 | 5.23 |
| 11:02 ET | 400 | 5.248 |
| 11:04 ET | 100 | 5.21 |
| 11:06 ET | 200 | 5.19 |
| 11:08 ET | 1332 | 5.2 |
| 11:15 ET | 300 | 5.225 |
| 11:22 ET | 1104 | 5.19 |
| 11:24 ET | 100 | 5.175 |
| 11:26 ET | 300 | 5.15 |
| 11:27 ET | 100 | 5.165 |
| 11:29 ET | 100 | 5.15 |
| 11:31 ET | 200 | 5.13 |
| 11:33 ET | 600 | 5.1899 |
| 11:36 ET | 476 | 5.13 |
| 11:45 ET | 500 | 5.1 |
| 11:47 ET | 100 | 5.1 |
| 11:49 ET | 100 | 5.09 |
| 11:54 ET | 500 | 5.085 |
| 11:56 ET | 200 | 5.085 |
| 11:58 ET | 1000 | 5.07 |
| 12:00 ET | 100 | 5.05 |
| 12:02 ET | 400 | 5.05 |
| 12:03 ET | 500 | 5.06 |
| 12:07 ET | 2392 | 5.09 |
| 12:09 ET | 100 | 5.0864 |
| 12:16 ET | 2908 | 5.13 |
| 12:18 ET | 100 | 5.115 |
| 12:21 ET | 1001 | 5.0925 |
| 12:23 ET | 400 | 5.09 |
| 12:25 ET | 877 | 5.15 |
| 12:27 ET | 100 | 5.17 |
| 12:30 ET | 1326 | 5.1525 |
| 12:32 ET | 100 | 5.15 |
| 12:34 ET | 800 | 5.16 |
| 12:36 ET | 2705 | 5.225 |
| 12:41 ET | 1269 | 5.26 |
| 12:43 ET | 870 | 5.28 |
| 12:45 ET | 769 | 5.255 |
| 12:48 ET | 100 | 5.255 |
| 12:50 ET | 100 | 5.255 |
| 12:52 ET | 1500 | 5.25 |
| 12:54 ET | 300 | 5.285 |
| 12:57 ET | 400 | 5.3 |
| 12:59 ET | 200 | 5.28 |
| 01:01 ET | 300 | 5.29 |
| 01:03 ET | 763 | 5.275 |
| 01:06 ET | 200 | 5.275 |
| 01:10 ET | 200 | 5.275 |
| 01:14 ET | 2729 | 5.29 |
| 01:15 ET | 300 | 5.29 |
| 01:17 ET | 400 | 5.3198 |
| 01:24 ET | 100 | 5.29 |
| 01:26 ET | 100 | 5.305 |
| 01:28 ET | 100 | 5.29 |
| 01:30 ET | 100 | 5.29 |
| 01:32 ET | 100 | 5.29 |
| 01:33 ET | 232 | 5.2901 |
| 01:35 ET | 736 | 5.27 |
| 01:37 ET | 100 | 5.26 |
| 01:39 ET | 300 | 5.25 |
| 01:44 ET | 100 | 5.25 |
| 01:46 ET | 200 | 5.25 |
| 01:48 ET | 2770 | 5.2881 |
| 01:51 ET | 100 | 5.271 |
| 01:53 ET | 500 | 5.2917 |
| 01:55 ET | 400 | 5.295 |
| 01:57 ET | 300 | 5.285 |
| 02:00 ET | 3219 | 5.25 |
| 02:02 ET | 1946 | 5.27 |
| 02:04 ET | 12454 | 5.1901 |
| 02:09 ET | 100 | 5.2 |
| 02:11 ET | 800 | 5.205 |
| 02:13 ET | 200 | 5.215 |
| 02:20 ET | 100 | 5.205 |
| 02:22 ET | 400 | 5.2141 |
| 02:24 ET | 909 | 5.19 |
| 02:27 ET | 500 | 5.15 |
| 02:29 ET | 100 | 5.155 |
| 02:31 ET | 400 | 5.15 |
| 02:33 ET | 400 | 5.13 |
| 02:36 ET | 200 | 5.14 |
| 02:38 ET | 200 | 5.16 |
| 02:42 ET | 100 | 5.12 |
| 02:44 ET | 100 | 5.12 |
| 02:45 ET | 301 | 5.13 |
| 02:47 ET | 1790 | 5.17 |
| 02:49 ET | 106 | 5.175 |
| 02:51 ET | 200 | 5.175 |
| 02:54 ET | 400 | 5.2 |
| 02:58 ET | 200 | 5.2 |
| 03:02 ET | 100 | 5.2 |
| 03:05 ET | 100 | 5.2 |
| 03:07 ET | 200 | 5.2 |
| 03:09 ET | 400 | 5.21 |
| 03:12 ET | 2798 | 5.29 |
| 03:14 ET | 2209 | 5.25 |
| 03:18 ET | 460 | 5.24 |
| 03:21 ET | 1428 | 5.16 |
| 03:23 ET | 100 | 5.16 |
| 03:25 ET | 300 | 5.15 |
| 03:27 ET | 250 | 5.15 |
| 03:30 ET | 203 | 5.17 |
| 03:32 ET | 200 | 5.17 |
| 03:34 ET | 300 | 5.15 |
| 03:36 ET | 300 | 5.165 |
| 03:38 ET | 300 | 5.165 |
| 03:39 ET | 1656 | 5.13 |
| 03:41 ET | 2690 | 5.1 |
| 03:43 ET | 1000 | 5.09 |
| 03:45 ET | 200 | 5.095 |
| 03:48 ET | 2860 | 5.09 |
| 03:50 ET | 900 | 5.125 |
| 03:52 ET | 555 | 5.1101 |
| 03:54 ET | 2123 | 5.11 |
| 03:56 ET | 800 | 5.12 |
| 03:57 ET | 2407 | 5.125 |
| 03:59 ET | 2544 | 5.14 |
Apr 9, 2024
DJ Syros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotene, from 2:09PM ET on Tuesday Apr 09, 2024 by Dow Jones
2:09PM ET on Tuesday Apr 09, 2024 by Dow JonesDJ Syros Gets FDA Fast-Track Designation for Tamibarotene, from 7:19AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:19AM ET on Tuesday Apr 09, 2024 by Dow JonesSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression, from 7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 3, 2024
DJ Syros Pharmaceuticals Price Target Maintained With a $13.00/Share by Piper Sandler, from 12:12PM ET on Wednesday Apr 03, 2024 by Dow Jones
12:12PM ET on Wednesday Apr 03, 2024 by Dow Jones
Apr 2, 2024
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Tuesday Apr 02, 2024 by Dow Jones
4:30PM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Syros Pharmaceuticals Inc | 132.0M | -0.9x | --- |
Vaxart Inc | 132.6M | -1.3x | --- |
Molecular Partners AG | 131.9M | -1.9x | --- |
Clearside Biomedical Inc | 105.4M | -2.6x | --- |
Coya Therapeutics Inc | 116.7M | -9.8x | --- |
Omega Therapeutics Inc | 131.8M | -1.3x | --- |
Company Information
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Contact Information
- Headquarters
- 35 Cambridge Park DriveCAMBRIDGE, MA, United States 02140
- Phone
- 617-744-1340
- Fax
- 617-744-1377
Executives
- Independent Chairman of the Board
- Peter Wirth
- President, Chief Executive Officer, Director
- Conley Chee
- Chief Financial Officer
- Jason Haas
- Senior Advisor
- Gerald Quirk
- Chief Medical Officer
- David Roth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $132.0M |
|---|---|
Revenue (TTM) | $9.9M |
Shares Outstanding | 26.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.77 |
EPS | $-5.77 |
Book Value | $0.63 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 13.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,298.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
